Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients
10.3760/cma.j.cn371439-20240115-00059
- VernacularTitle:血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究
- Author:
Hongjian CHEN
1
;
Suqing ZHANG
Author Information
1. 南通大学附属肿瘤医院肝胆胰外科，南通 226361
- Keywords:
Liver neoplasms;
Serum;
Recurrence;
MicroRNA-24-3p;
H2A histone family member X
- From:
Journal of International Oncology
2024;51(6):344-349
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the relationship between serum microRNA (miR) -24-3p, H2A histone family member X (H2AFX) and clinical pathological features and postoperative recurrence in liver cancer patients.Methods:A total of 108 newly diagnosed liver cancer patients admitted to Tumor Hospital Affiliated to Nantong University from March 2018 to March 2022 were regarded as the liver cancer group. Eighty-six patients with benign liver lesions who visited our hospital during the same period were selected as the benign lesion group, and 64 healthy individuals who underwent physical examinations were selected as the control group. Quantitative real-time PCR method was applied to detect and analyze the levels of serum miR-24-3p and H2AFX mRNA in each group. The serum miR-24-3p and H2AFX levels in patients with recurrent and non-recurrent liver cancer were compared, and the comparison of clinicopathological characteristics of patients with liver cancer with different serum miR-24-3p and H2AFX levels was conducted. Logistic regression was applied to analyze the risk factors affecting postoperative recurrence in liver cancer patients.Results:To the end of follow-up, of the 108 patients with liver cancer, 46 relapsed. The serum miR-24-3p levels in control group, benign lesion group, and liver cancer group were 1.01±0.23, 0.79±0.21 and 0.55±0.13, respectively, with a statistically significant difference ( F=125.86, P<0.001), serum miR-24-3p level in benign lesion group and liver cancer group was lower than that in control group (both P<0.05), and serum miR-24-3p level in liver cancer group was lower than that in benign lesion group ( P<0.05). The serum H2AFX mRNA levels in control group, benign lesion group, and liver cancer group were 1.02±0.25, 1.27±0.31 and 1.59±0.37, respectively, with a statistically significant difference ( F=65.40, P<0.001), serum miR-24-3p level in benign lesion group and liver cancer group were higher than that in control group (both P<0.05), and serum miR-24-3p level in liver cancer group was higher than that in benign lesion group ( P<0.05). There were statistically significant differences in TNM stage ( χ2=7.85, P=0.005; χ2=6.32, P=0.012) and differentiation degree ( χ2=11.59, P=0.001; χ2=9.92, P=0.002) between patients with high and low level of miR-24-3p and H2AFX. Compared with the non-relapsed patients, the serum miR-24-3p level was significantly lower (0.44±0.12 vs. 0.64±0.14) and the H2AFX level was significantly higher (1.87±0.42 vs. 1.38±0.33) among the relapsed patients, with statistically significant differences ( t=7.79, P<0.001; t=6.79, P<0.001). Univariate analysis showed that TNM stage ( OR=1.57, 95% CI: 1.05-2.35, P=0.029), differentiation degree ( OR=2.20, 95% CI: 1.20-4.02, P=0.011), miR-24-3p level ( OR=0.66, 95% CI: 0.45-0.95, P=0.026), H2AFX level ( OR=1.73, 95% CI: 1.14-2.60, P=0.009) were all influential factors for postoperative recurrence in liver cancer patients. Multifactorial analysis showed that TNM stage ( OR=2.10, 95% CI: 1.14-3.86, P=0.017), differentiation degree ( OR=1.58, 95% CI: 1.12-2.23, P=0.009), miR-24-3p level ( OR=0.76, 95% CI: 0.63-0.92, P=0.005), H2AFX level ( OR=1.90, 95% CI: 1.20-2.99, P=0.006) were the independent influencing factors of postoperative recurrence in liver cancer patients. Conclusion:There are statistically significant differences in tumor TNM stage and differentiation degree among liver cancer patients with different serum miR-24-3p and H2AFX levels, and serum miR-24-3p and H2AFX levels are the influencing factors for postoperative recurrence in liver cancer patients.
